GB201301771D0 - A formulation for the treatment of chronic fatigue syndrome,chronic fatigue,fibromyalgia and depression - Google Patents

A formulation for the treatment of chronic fatigue syndrome,chronic fatigue,fibromyalgia and depression

Info

Publication number
GB201301771D0
GB201301771D0 GBGB1301771.0A GB201301771A GB201301771D0 GB 201301771 D0 GB201301771 D0 GB 201301771D0 GB 201301771 A GB201301771 A GB 201301771A GB 201301771 D0 GB201301771 D0 GB 201301771D0
Authority
GB
United Kingdom
Prior art keywords
chronic fatigue
fibromyalgia
depression
formulation
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB1301771.0A
Other versions
GB2510374A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB1301771.0A priority Critical patent/GB2510374A/en
Publication of GB201301771D0 publication Critical patent/GB201301771D0/en
Priority to GB1321945.6A priority patent/GB2510477B/en
Publication of GB2510374A publication Critical patent/GB2510374A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5939,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004Monosaccharides having only carbon, hydrogen and oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258Panax (ginseng)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/82Theaceae (Tea family), e.g. camellia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
GB1301771.0A 2013-01-31 2013-01-31 Formulation comprising N-acetylcarnitine and D-ribose Withdrawn GB2510374A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB1301771.0A GB2510374A (en) 2013-01-31 2013-01-31 Formulation comprising N-acetylcarnitine and D-ribose
GB1321945.6A GB2510477B (en) 2013-01-31 2013-12-11 Formulations for use in the treatment of chronic fatigue and associated conditions, etc

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1301771.0A GB2510374A (en) 2013-01-31 2013-01-31 Formulation comprising N-acetylcarnitine and D-ribose

Publications (2)

Publication Number Publication Date
GB201301771D0 true GB201301771D0 (en) 2013-03-20
GB2510374A GB2510374A (en) 2014-08-06

Family

ID=47988520

Family Applications (2)

Application Number Title Priority Date Filing Date
GB1301771.0A Withdrawn GB2510374A (en) 2013-01-31 2013-01-31 Formulation comprising N-acetylcarnitine and D-ribose
GB1321945.6A Expired - Fee Related GB2510477B (en) 2013-01-31 2013-12-11 Formulations for use in the treatment of chronic fatigue and associated conditions, etc

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB1321945.6A Expired - Fee Related GB2510477B (en) 2013-01-31 2013-12-11 Formulations for use in the treatment of chronic fatigue and associated conditions, etc

Country Status (1)

Country Link
GB (2) GB2510374A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114208971A (en) * 2021-11-29 2022-03-22 中国科学院水生生物研究所 Application of D-ribose in feed for improving flavor and meat quality of crucian

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017120731A1 (en) * 2016-01-11 2017-07-20 Shanghai Yao Yuan Biotechnology Co., Ltd. Methods and compositions for reducing body weight

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022052A1 (en) * 2000-04-06 2002-02-21 Dransfield Charles William Transdermal delivery system
IT1317043B1 (en) * 2000-06-14 2003-05-26 Sigma Tau Healthscience Spa FOOD SUPPLEMENT ENHANCING THE ENERGETIC-MUSCULAR METABOLISM, INCLUDING AN ALCANOIL L-CARNITINE AND RIBOSE.
AU2002359618A1 (en) * 2001-12-06 2003-06-23 Weller Health, Inc. Medicinal compositions and therapeutic methods
US20040241256A1 (en) * 2002-12-05 2004-12-02 Seymour Ehrenpreis Medicinal compositions & therapeutic methods
JP4754484B2 (en) * 2004-03-18 2011-08-24 田辺三菱製薬株式会社 Depressive symptom improving agent
US20080233245A1 (en) * 2007-03-19 2008-09-25 Lesley Joan White Liquid nutrient composition for improving performance
US8466198B2 (en) * 2008-09-02 2013-06-18 Bruce Kneller Compositions comprising creatine salts and methods of use thereof
TW201201712A (en) * 2010-01-28 2012-01-16 Max International Llc Compositions comprising sugar-cysteine products
US20130059038A1 (en) * 2011-09-01 2013-03-07 John C. Gilkey Nutritional composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114208971A (en) * 2021-11-29 2022-03-22 中国科学院水生生物研究所 Application of D-ribose in feed for improving flavor and meat quality of crucian

Also Published As

Publication number Publication date
GB2510477B (en) 2017-12-13
GB2510477A (en) 2014-08-06
GB201321945D0 (en) 2014-01-22
GB2510374A (en) 2014-08-06

Similar Documents

Publication Publication Date Title
HK1220918A1 (en) Cytokine derived treatment with reduced vascular leak syndrome
GB201409813D0 (en) Methods, apparatuses and computer programs for adapting content
HUE054577T2 (en) Fenfluramine for use in the treatment of dravet syndrome
EP3019082A4 (en) Determining respiratory parameters
IL244427A0 (en) Systems, devices and methods for anti-tl1a therapy
EP2999421A4 (en) Cyrogenic treatment systems
EP3035993A4 (en) Selecting and delivering treatment agents based on a microbe profile
GB201417264D0 (en) Content mirroring
EP3357679A4 (en) Humidifying device and corrugating machine
HUE044207T2 (en) A modified surface capable of having bacteriostatic and bactericide activity, the method for obtaining it and use thereof
GB201401711D0 (en) Non-uniform constellations
GB201408673D0 (en) Medicaments,uses and methods
GB2553840B (en) Robots, methods, computer programs and computer-readable media
EP3022298A4 (en) Attenuated influenza vaccines and uses thereof
EP3007834A4 (en) Device for, or in, the surface treatment of objects
PL3488612T3 (en) Apparatuses, methods, computer programs and computer-readable media
EP2640397A4 (en) Methods for the treatment of fibromyalgia and chronic fatigue syndrome
HK1250626A1 (en) Combination treatments with seribantumab
EP3065726A4 (en) Creatine analogs and the use thereof
HK1258293A1 (en) Assistance implement for ameliorating sleep apnea syndrome
GB201301771D0 (en) A formulation for the treatment of chronic fatigue syndrome,chronic fatigue,fibromyalgia and depression
GB2538877B (en) Passive NOx adsorber
PL2835245T3 (en) Two component condensate hose
AU2013901661A0 (en) A treatment and diagnosis of chronic fatigue syndrome
GB201314141D0 (en) P9

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)